Dr. Grey AI

Acromegaly

Research on acromegaly, a hormonal disorder caused by excess growth hormone production, typically from a pituitary adenoma. Studies evaluate GH and IGF-1 normalization, symptom control, and tumor management.

Quick Answer

What it is

Research on acromegaly, a hormonal disorder caused by excess growth hormone production, typically from a pituitary adenoma. Studies evaluate GH and IGF-1 normalization, symptom control, and tumor management.

Key findings

  • Grade A: GH Suppression (Acromegaly) (Octreotide (Sandostatin))
  • Grade A: IGF-1 Normalization (Octreotide (Sandostatin))
  • Grade A: Acromegaly Symptoms (Octreotide (Sandostatin))

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

ℹ️ Quick Facts

Quick Facts: Acromegaly

  • Supplements Studied:4
4 supps · 13 outcomes

Detailed Outcomes

|
A
GH Suppression (Acromegaly)
Meta-analysis shows 56% achieve GH control (<2.5 ÎĽg/L). ACROINNOVA 1 showed 72% response rate for IGF-1 normalization with octreotide depot.
large↓Improves
A
IGF-1 Normalization
55% achieve IGF-1 normalization in meta-analysis. Oral octreotide maintained response in 65% of previously controlled patients.
large↓Worsens
A
Acromegaly Symptoms
Treatment reduces soft tissue swelling, headaches, and other symptoms associated with excess GH/IGF-1.
moderate↓Improves
A
GH Suppression (Acromegaly)
Pasireotide LAR provides GH/IGF-1 control in acromegaly patients, including some resistant to octreotide or lanreotide due to broader receptor binding.
large↓Improves
A
IGF-1 Normalization
Significantly greater IGF-1 normalization rates compared to octreotide LAR in some studies, particularly in patients with inadequate control on first-generation somatostatin analogs.
large↓Worsens
A
GH Suppression (Acromegaly)
50-60% of patients achieve GH control (<2.5 ng/mL) with long-term lanreotide treatment. FDA-approved for acromegaly.
large↓Improves
A
IGF-1 Normalization
Approximately 50% of acromegaly patients achieve IGF-1 normalization with lanreotide depot treatment.
large↓Worsens
A
Acromegaly Symptoms
Significant improvement in soft tissue swelling, headaches, joint pain, and fatigue associated with acromegaly.
moderate↓Improves
A
IGF-1 Normalization
97% achieved normal IGF-1 at 12 months in clinical trials. Phase III: 89% normalization with 20mg daily dose. Most effective medical therapy for biochemical control.
large↓Worsens
A
Serum IGF-1 Levels
Dose-dependent reduction: 62.5% decrease with 20mg/day vs 4% with placebo. German Observational Study showed sustained reduction from 1.75x to 0.89x ULN over 24 months.
large↓Improves
A
Treatment-Resistant Acromegaly
100% IGF-1 normalization in octreotide-resistant patients. Effective after failed surgery and somatostatin analog therapy.
large↓Improves
A
Glucose Metabolism
Significant decrease in serum insulin and glucose concentrations (P<0.05). Particularly beneficial in acromegaly patients with coexistent diabetes mellitus.
moderate↓Improves
A
Acromegaly Symptoms
Improvement in soft tissue swelling, fatigue, perspiration, and joint symptoms associated with GH/IGF-1 excess.
moderate↓Improves

Research Citations (100)

Lanreotide protects against LPS-induced inflammation in endothelial cells and mouse lungs.
(2025)
PMID: 40241488
Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.
(2025)
PMID: 40437077
Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.
(2025)
PMID: 40468101
Variations in Octreotide Dosing in Published Reports of Sulfonylurea Toxicity: A Systematic Review, 1988-Present.
(2025)
PMID: 39821850
The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: A narrative review.
(2025)
PMID: 40629899
Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis.
(2025)
PMID: 39527181
Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia.
(2025)
PMID: 40165498
Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.
(2025)
PMID: 39842795
Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis.
(2025)
PMID: 40622518
Personalized medicine in acromegaly: insights from the ACROFAST clinical trial.
(2025)
PMID: 41020777

Related Conditions

Neuroendocrine Tumors

2 shared supplements · 12 outcomes

Research on neuroendocrine tumors (NETs) including carcinoid tumors, pancreatic NETs, and gastroenteropancreatic NETs. Studies evaluate tumor control, symptom management, and survival outcomes.

Cushing's Disease

1 shared supplement · 3 outcomes

Research on Cushing's disease, a condition caused by excess cortisol production typically due to a pituitary adenoma secreting ACTH. Studies evaluate urinary free cortisol normalization, ACTH suppression, and clinical symptom improvement.